stockrow
Saturday 7 November 2026
Export MNKD’s income statement to Excel — free account
MannKind Corporation
MNKD Healthcare Biotechnology
MannKind Corporation’s revenue for fiscal 2025 (year ended December 2025) was $349.0 million, up 22.2% from fiscal 2024.
- Revenue
- +24.0%
- EPS
- −333.3%
- Free cash flow
- −267.7%
- Total debt
- +201.8%
Quarter to September 2026, against a year earlier
3.92
0.16
+4.26%
Follow MNKD
Alert me
| Sep '26 From the 10-Q filed 5 Nov | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 255.41 |
+8 more quarters Free account |
P/S ratio |
3.02 | 3.35 | 2.09 | 4.97 | |
P/FCF ratio |
0.00 | 0.00 | 57.43 | 126.60 | |
P/Operating CF |
(36.14) | (71.70) | (140.77) | (217.76) | |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
3.81 | 4.14 | 2.89 | 5.79 | |
EV/EBITDA |
50.03 | 51.74 | 32.02 | 38.89 | |
EV/Operating CF |
(23.76) | (202.15) | 54.15 | 110.64 | |
EV/FCF |
(20.08) | (89.78) | 79.33 | 147.54 | |
Quick Ratio |
1.27 | 1.08 | 1.20 | 1.23 | |
Current Ratio |
2.22 | 1.72 | 1.87 | 1.70 | |
Net Debt/EBITDA |
0.00 | 45.02 | 50.54 | (95.76) | |
Debt/Assets |
0.00% | 57.64% | 56.68% | 57.82% | |
Debt/Equity |
0.00 | (6.28) | (7.13) | (8.98) | |
Asset Turnover |
0.68 | 0.69 | 0.63 | 0.59 | |
Operating CF/Net income |
1.49 | 0.97 | 0.32 | 0.50 | |
Capex/Depreciation |
0.00 | (0.70) | (0.26) | (0.42) | |
Interest Coverage |
— | (0.02) | (0.13) | (0.55) | |
Research and Development Expense of Revenue |
14.10% | 16.46% | 19.11% | 24.64% | |
Selling, General and Administrative Expense of Revenue |
60.28% | 53.31% | 59.98% | 52.17% | |
Intangible Assets out of Total Assets |
0.10 | 0.10 | 0.10 | 0.09 | |
Share Based Compensation of Revenue |
0.00% | 9.35% | 7.16% | 14.67% | |
Graham Net Nets |
(0.42) | (0.42) | (0.73) | (0.32) | |
Graham Number |
0.78 | 0.80 | 0.54 | 0.00 | |
Earnings Yield |
(5.90%) | (3.05%) | (2.77%) | 0.39% | |
Free Cash Flow Yield |
(6.28%) | (1.38%) | 1.74% | 0.79% | |
Revenue per Share |
0.32 | 0.35 | 0.29 | 0.37 | |
Operating CF per Share |
(0.11) | (0.06) | (0.02) | (0.03) | |
Capex per Share |
(0.01) | (0.02) | (0.01) | (0.01) | |
Free Cash Flow per Share |
(0.12) | (0.08) | (0.02) | (0.03) | |
Cash per Share |
0.30 | 0.36 | 0.43 | 0.56 | |
Shareholders Equity per Share |
(0.12) | (0.22) | (0.19) | (0.17) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(0.12) | (0.22) | (0.19) | (0.17) | |
Free Cash Flow |
(37.76) | (23.45) | (7.24) | (9.95) | |
Working Capital |
131.95 | 102.81 | 116.60 | 120.55 | |
Capital Expenditures |
(3.21) | (5.08) | (1.88) | (1.99) | |
Net Current Asset Value |
(519.41) | (553.79) | (552.44) | (551.62) | |
EV/EBIT |
0.00 | 177.12 | 70.30 | 52.05 | |
Capex to Sales |
0.03 | 0.05 | 0.02 | 0.02 | |
Price to Operating Income |
0.00 | 143.29 | 50.89 | 44.66 | |
| Other line items | |||||
Average Receivables |
29.21 | 35.17 | 28.52 | 25.09 | |
Average Payables |
10.83 | 10.65 | 10.59 | 7.91 | |
Average Inventory |
37.72 | 36.46 | 39.03 | 31.60 | |
Average Assets |
608.63 | 572.00 | 577.27 | 593.01 | |
Average Common Equity |
(40.91) | (61.12) | (58.91) | (64.92) |
Columns are period end dates · fundamentals updated 5 Nov 2026